{"created":"2023-05-15T14:50:32.908904+00:00","id":69127,"links":{},"metadata":{"_buckets":{"deposit":"e881b854-6965-49a1-8255-fdf8d4302029"},"_deposit":{"created_by":1,"id":"69127","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"69127"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00069127","sets":["10:28"]},"author_link":["678339","678350","678338","678342","678349","678351","678347","678336","678346","678344","678343","678345","678348","678340","678337","678341"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2007-10-07","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Introduction: A phase II study of Carbon Ion Radiotherapy (CIRT) for HCC according to a 52.8 cobalt gray equivalent (GyE) /4-fraction/1-week regime was conducted from April 2001 to February 2003. Purpose: To evaluate the efficacy of 4-fraction CIRT for HCC. Methods: Eligibility criteria were as follows: biopsy-proven, recurrent or residual tumor after other treatments or no indication for any other treatment; no prior radiotherapy for target tumors; Child-Pugh grade A or B. Results: Forty-seven patients with chronic liver disease of Child-Pugh grade A in 37, B in 10 were enrolled. The median age at therapy was 69 years. The median tumor size was 3.7 (1.2-7.5)cm in diameter. During a median follow-up of 60 (48-70)months, no treatment-related hepatic failure and death occurred. Incidence of grade 3 early hepatic toxicity in the serum-GPT, ALB, T.BIL, PT and ALP according to NCI-CTC (ver.2) was 0, 11, 0, 2, and 13%, respectively. No other grade 3 or worse adverse effect occurred. In 92% of patients, the Child-Pugh score did not increase by more than 1 point within 1 year after the therapy. Local control rate was 96% at 1 to 5 years. Overall and cause-specific survival rates at 3 and 5 years were 57% and 67%, 34% and 42%, respectively. Those in the 27 patients initially treated with CIRT were 63% and 81%, 40% and 52%, respectively. Conclusion: Four-fraction CIRT for HCC seems to have a promising potential as a new, radical, and minimally invasive therapeutic option for HCC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"ILCA's First Annual Conference","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Katou, Hirotoshi"}],"nameIdentifiers":[{"nameIdentifier":"678336","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Shigeru"}],"nameIdentifiers":[{"nameIdentifier":"678337","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo"}],"nameIdentifiers":[{"nameIdentifier":"678338","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maeda, Yukiteru"}],"nameIdentifiers":[{"nameIdentifier":"678339","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"678340","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mizoe, Junetsu"}],"nameIdentifiers":[{"nameIdentifier":"678341","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ootou, Masao"}],"nameIdentifiers":[{"nameIdentifier":"678342","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"678343","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 博敏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678344","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山田 滋","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678345","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"安田 茂雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678346","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"前田 幸輝","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678347","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678348","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"溝江 純悦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678349","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大藤 正雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678350","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"678351","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-10-12"},"publish_date":"2007-10-12","publish_status":"0","recid":"69127","relation_version_is_last":true,"title":["Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:18:10.725721+00:00"}